Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAR441000 |
Synonyms | |
Therapy Description |
SAR441000 is a mixture of mRNA encoding IL-12sc, IL-15sushi, IFNa and GM-CSF that may be taken up by cells, translated, and released into the tumor microenvironment, potentially resulting in increased antitumor immune response (NCI Drug Dictionary; Cancer Res (2023) 83 (8_Supplement): LB198). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR441000 | SAR 441000|SAR-441000|BNT 131|BNT131|BNT-131 | SAR441000 is a mixture of mRNA encoding IL-12sc, IL-15sushi, IFNa and GM-CSF that may be taken up by cells, translated, and released into the tumor microenvironment, potentially resulting in increased antitumor immune response (NCI Drug Dictionary; Cancer Res (2023) 83 (8_Supplement): LB198). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03871348 | Phase I | SAR441000 Cemiplimab + SAR441000 | A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Terminated | USA | NLD | FRA | ESP | DEU | BEL | 0 |